G1 Therapeutics, Inc. (GTHX)

NASDAQ: GTHX · IEX Real-Time Price · USD
4.120
-0.050 (-1.20%)
Apr 19, 2024, 3:40 PM EDT - Market open
-1.20%
Market Cap 214.54M
Revenue (ttm) 82.51M
Net Income (ttm) -47.97M
Shares Out 52.20M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 657,400
Open 4.130
Previous Close 4.170
Day's Range 3.965 - 4.305
52-Week Range 1.080 - 5.000
Beta 1.70
Analysts Buy
Price Target 10.80 (+162.14%)
Earnings Date May 1, 2024

About GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L m... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 17, 2017
Employees 100
Stock Exchange NASDAQ
Ticker Symbol GTHX
Full Company Profile

Financial Performance

In 2023, GTHX's revenue was $82.51 million, an increase of 60.84% compared to the previous year's $51.30 million. Losses were -$47.97 million, -67.49% less than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for GTHX stock is "Buy." The 12-month stock price forecast is $10.8, which is an increase of 162.14% from the latest price.

Price Target
$10.8
(162.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financ...

2 days ago - GlobeNewsWire

G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Baile...

15 days ago - GlobeNewsWire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerci...

17 days ago - GlobeNewsWire

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

- Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - N...

7 weeks ago - GlobeNewsWire

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey...

7 weeks ago - GlobeNewsWire

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financia...

2 months ago - GlobeNewsWire

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC

2 months ago - GlobeNewsWire

G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference

- Initial Data from the Ongoing Phase 2 Trial in Combination with the Antibody-Drug Conjugate (ADC) Sacituzumab Govitecan (SG) Suggest a Potentially Meaningful Improvement in Overall Survival (OS) for...

3 months ago - GlobeNewsWire

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey...

3 months ago - GlobeNewsWire

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent

4 months ago - GlobeNewsWire

G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that an abstract exploring the long-term impa...

5 months ago - GlobeNewsWire

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

- Recognized Total Revenue of $12.3 Million, Including $10.8 Million in Net COSELA® (trilaciclib) Revenue; Vial Volume Grew 3% Over Prior Quarter - - Confirmed Expectation of Interim Overall Survival ...

6 months ago - GlobeNewsWire

Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Trilaciclib Reduces Hospitalizations and Myelosuppressive Events in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) and May Improve Survival

6 months ago - GlobeNewsWire

G1 Therapeutics' COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)

RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that COSELA® (trilaciclib) has been recommend...

6 months ago - GlobeNewsWire

G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023

RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financia...

6 months ago - GlobeNewsWire

G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium

RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that multiple abstracts have been accepted fo...

6 months ago - GlobeNewsWire

G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Communications Officer Will Robert...

8 months ago - GlobeNewsWire

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights

- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA® (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial...

9 months ago - GlobeNewsWire

G1 Therapeutics to Participate in Two August Investor Conferences

RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August invest...

9 months ago - GlobeNewsWire

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and Thrombocytopenia -

9 months ago - GlobeNewsWire

G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023

RESEARCH TRIANGLE PARK, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financia...

9 months ago - GlobeNewsWire

Cancer drugmakers rise as industry meet fuels investor interest

Shares of several cancer drug firms surged on Monday after the companies reported positive clinical trial data from their therapies at an ongoing industry conference in Chicago.

Other symbols: DAWNEVAX
11 months ago - Reuters

Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy

- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment -

11 months ago - GlobeNewsWire

G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the Appointment The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Con...

11 months ago - GlobeNewsWire

New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer

Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive...

1 year ago - GlobeNewsWire